Rucaparib was evaluated in a phase II trial as a maintenance regimen for advanced pancreatic cancer (including both metastatic and locally advanced cases) in patients harboring BRCA1, BRCA2 or PALB2 germline or somatic mutations. Here, PALB2 is linked to familial pancreatic carcinoma.